Who is sponsoring NCT03515772?

NCT03515772 is sponsored by Centre Hospitalier Universitaire Vaudois.

What drugs are being tested in NCT03515772?

Interventions in NCT03515772: Co-administration of darunavir with a cardiovascular drug.

What condition does NCT03515772 study?

NCT03515772 studies HIV Infections, Drug Interactions, Cardiovascular Diseases.

Is NCT03515772 still recruiting?

NCT03515772 is currently completed. Last updated 28 July 2020.

Last reviewed 2020-07-28 · How we verify

NCT03515772

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug-drug Interactions Between Antiretroviral Drugs and Cardiovascular Drugs in Elderly Patients

Completed Last updated 28 July 2020

What this trial tests

trial testing Co-administration of darunavir with a cardiovascular drug in HIV Infections in 21 participants. Completed in 29 August 2019.

Timeline

23 April 2018

Primary endpoint
29 August 2019

29 August 2019

Quick facts

Lead sponsor	Centre Hospitalier Universitaire Vaudois
Status	Completed
Study type	OBSERVATIONAL
Enrollment	21
Start date	23 April 2018
Primary completion	29 August 2019
Estimated completion	29 August 2019
Sites	2 locations across Switzerland

Drugs / interventions tested

Co-administration of darunavir with a cardiovascular drug — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →
Drug Interactions — all drugs for Drug Interactions →
Cardiovascular Diseases — all drugs for Cardiovascular Diseases →

Sponsor

Centre Hospitalier Universitaire Vaudois

Who can join

Eligibility, any sex, with HIV Infections or Drug Interactions. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ageing is characterized by physiological changes, which can impact drug pharmacokinetics and thereby cause drug-drug interactions. This study aims to assess the pharmacokinetics of amlodipine, atorvastatin and rosuvastatin in the presence of darunavir/ritonavir (inhibitor of drug metabolizing enzymes and drug transporters), by comparison with dolutegravir (no inhibitory effects on cytochromes or transporters involved in the disposition of the evaluated co-medications), in order to characterize the importance of drug-drug interactions in elderly individuals.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.
Courlet P, Guidi M, Alves Saldanha S, Cavassini M, et al · · 2021 · cited 10× · PMID 33452585 · DOI 10.1007/s00228-020-03060-2
Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV.
Courlet P, Guidi M, Alves Saldanha S, Stader F, et al · · 2021 · cited 5× · PMID 33124006 · DOI 10.1007/s40262-020-00946-3
Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV.
Courlet P, Decosterd LA, Alves Saldanha S, Cavassini M, et al · · 2020 · cited 5× · PMID 32281059 · DOI 10.1007/s40262-020-00876-0

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other Centre Hospitalier Universitaire Vaudois trials

Trials by the same sponsor.

NCT07427511 — SwissNeuroRehab - HDHI · NA · recruiting
NCT07263438 — Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a · Phase 2 · recruiting
NCT07139756 — Deciphering the Mechanisms of Central BP Regulation in Patients With PD Associated With Orthostatic Hypotension · not yet recruiting
NCT07109388 — Comparison of Pericapsular Nerve Group (PENG) Block With a Combined Femoral, Sciatic, Lateral Femoral Cutaneous Nerve Bl · NA · not yet recruiting
NCT07268378 — Supervision of Clinicians in Oncology by Psycho-oncologists : Evaluation · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03515772 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire Vaudois
Last refreshed: 28 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03515772.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing